Clinical trials: Cell Transplantation
Stem Cell Transplant Complications
Pro-ADM vs PCT in Patients With Complications Post Hematopoietic Stem Cell Transplantation
Prospective, multicenter, spontaneous, non-interventional, non pharmacological. Study aimed at evaluate kinetics, diagnostic and prognostic value of pro-ADM (proadrenomedullin) as compared to PCT (procalcitonin) in patients…
- Trial name
- NCT05523336
- Testing
- observation
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
Hodgkin's Disease
Allogeneic Blood Stem Cell Transplantation
1. To determine the feasibility and toxicity of employing allogeneic peripheral blood stem cell transplantation after intensive but non-myeloablative chemotherapy in patients with relapsed Hodgkin's disease (HD). 2.
- Trial name
- NCT00423709
- Testing
- Allogeneic Blood Stem Cell Transplantation, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Acute GVHD
Ruxolitinib and Steroid As First Line Therapy for Acute GVHD
The purpose of this study is to evaluate the efficacy of ruxolitinib in combination with methylprednisolone as first line therapy in patients with Grades II to IV acute graft-versus-host disease (GVHD).
- Trial name
- NCT03701698
- Testing
- Ruxolitinib Oral Tablet, Methylprednisolone
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hematopietic Stem Cell Transplantation, Blood Virome
DNA and RNA Viruses of the Blood Virome of Allogeneic Hematopoietic Stem Cell Transplant Recipients
The Geneva Blood Virome Project is a longitudinal observational study. The main objective is to describe the kinetics of the plasmatic viral load of a selection of at least 21 DNA and RNA viruses of the blood virome in allogeneic…
- Conditions
- Hematopietic Stem Cell Transplantation, Blood Virome, RNA Virus Infections, DNA Virus Infections
- Trial name
- GeBVir (NCT03642977)
- Testing
- Real time PCR and RT-PCR for DNA and RNA viral species
- Where
- Switzerland
- Volunteers
- 112 people
- Sponsor
- University Hospital, Geneva
Hodgkin's Lymphoma, Multiple Myeloma
Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant
Nestle Impact has shown efficacy in multiple surgical trials in relation to improving hospital length of stay and infection rate.
- Conditions
- Hodgkin's Lymphoma, Multiple Myeloma, Non-Hodgkin's Lymphoma
- Trial name
- NCT01699581
- Testing
- Nestle Impact Advanced Recovery
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Greg Monohan
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Historically, the best results of allogeneic SCT have been obtained when the stem cell donor is a human leukocyte antigen (HLA)-matched sibling, however, this is only available for approximately 30 percent of patients in need for…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Non-hodgkin Lymphoma
- Trial name
- NCT03088709
- Testing
- Cyclophosphamide, Tacrolimus, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Loyola University
Leukemia, Myeloid, Leukemia, Lymphocytic
T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation
T-cell and B-cell depletion in allogeneic peripheral blood stem cell transplantation by using immunomagnetic negative and positive selection procedures Background: Removal of T-cells from the donor graft (T-cell depletion) offers…
- Conditions
- Leukemia, Myeloid, Leukemia, Lymphocytic, Myelodysplastic Syndrome, Leukemia, Myeloid, Chronic
- Trial name
- NCT00306332
- Testing
- T-cell and B-cell depletion
- Where
- Netherlands
- Volunteers
- 250 people
- Sponsor
- Radboud University Medical Center
Aggressive Lymphoma, Diffuse Large B-cell Lymphoma
Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL
The purpose of this study is to determine efficacy of rituximab, gemcitabine, oxaliplatin and dexametasone (R-GemOx) chemotherapy schedule.
- Conditions
- Aggressive Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- RGemOx (NCT01562977)
- Testing
- Rituximab, Gemcitabine, Oxaliplatin, Dexametasone
- Where
- 28 sites in Spain
- Volunteers
- 82 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Cancer
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to chronic graft-versus-host disease in patients who…
- Trial name
- NCT00957736
- Testing
- polymorphism analysis, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 252 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hematopoietic Stem Cell Transplantation
PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
The granulocyte colony-stimulating factor (G-CSF)+antithymocyte globulin (ATG)-based protocols and posttransplantation cyclophosphamide (PTCy) protocols have been widely used for graft-versus-host disease (GVHD) prophylaxis in…
- Trial name
- NCT03689465
- Testing
- ATG, CTX, Mycophenolate Mofetil
- Where
- 7 sites in China
- Volunteers
- 260 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma
This clinical trial studies genetically modified peripheral blood stem cell transplant in treating patients with HIV-associated non-Hodgkin or Hodgkin lymphoma.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma
- Trial name
- NCT01769911
- Testing
- carmustine, cytarabine, melphalan
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Acute Leukemia, Myelodysplastic Syndromes
Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic Syndrome
This study is an open, prospective, single-center, single-arm study expanded based on the study of NCT03412409.The primary objective of this study is to evaluate the transplantation efficacy of the RIC conditioning regimen in…
- Trial name
- NCT05902416
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University People's Hospital
Cytomegalovirus Infections
Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant
Patients have a type of blood cell cancer, other blood disease or a genetic disease for which they will receive a stem cell transplant.
- Trial name
- VICTA (NCT00078533)
- Testing
- CMV CTL infusion
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Baylor College of Medicine
Multiple Myeloma
Autologous Transplant for Multiple Myeloma
This is a study of a regimen of melphalan and autologous stem cells for patients with multiple myeloma. We hypothesize that this particular regimen will improve the survival of these patients.
- Trial name
- NCT00177047
- Testing
- Stem Cell Transplant, Cyclophosphamide + Mesna, Melphalan
- Where
- United States
- Volunteers
- 363 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Leukemia, Chronic Leukemia
Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor
Genzyme will evaluate/monitor the off label transplant use of plerixafor using data in the European Group for Blood and Marrow Transplantation (EBMT) registry.
- Conditions
- Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
- Trial name
- NCT01362985
- Volunteers
- 201 people
- Sponsor
- Genzyme, a Sanofi Company
Sickle Cell Disease, Beta Thalassemia
Stem Cell Transplant in Sickle Cell Disease and Thalassemia
The primary purpose of this study is to see if giving lower doses of chemotherapy (moderately ablative) will result in successful bone marrow replacement without as severe side-effects but with permanent control of the disease.
- Trial name
- NCT00408447
- Testing
- Busulfan, Fludarabine, Alemtuzumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Columbia University
Multiple Myeloma and Plasma Cell Neoplasm
Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Giving bortezomib as maintenance therapy after autologous stem cell transplantation may kill more cancer cells and…
- Trial name
- NCT00084747
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Anemia, Sickle Cell, Complex and Transfusion-dependent Hemoglobinopathies
Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies
The goal of this research study is to establish chimerism and avoid graft-versus-host disease in patients with hemoglobinopathies.
- Conditions
- Anemia, Sickle Cell, Complex and Transfusion-dependent Hemoglobinopathies, Thalassemia, Diamond-Blackfan Anemia
- Trial name
- NCT01419704
- Testing
- Enriched Hematopoetic Stem Cell Infusion
- Where
- 3 sites in United States
- Sponsor
- Talaris Therapeutics Inc.
Graft Versus Host Disease, Leukemia
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
RATIONALE: Giving chemotherapy, such as clofarabine, melphalan, and thiotepa, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00423514
- Testing
- filgrastim, clofarabine, melphalan
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
End-Stage Renal Disease, Kidney Failure
Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection
T regulatory cells (T regs) are responsible for immune tolerance in solid organ transplant patients. This study will evaluate the treatment of children with kidney transplants either with Campath and other immune system…
- Trial name
- NCT01446484
- Testing
- CD4+CD25+CD127lowFoxP3+ T regulatory cells injection, Alemtuzumab, Mycophenolate mofetil
- Where
- 2 sites in Russia
- Volunteers
- 30 people
- Sponsor
- Pirogov Russian National Research Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.